Why the study?
Does the automated VWF Activity assay correlate with VWF:RCo for the diagnosis and subtyping of von Willebrand disease?
Does the automated VWF Activity assay correlate with VWF:RCo for the diagnosis and subtyping of von Willebrand disease?
Answers are grounded in this paper and cite their sources.
The automated VWF:Act assay combined with PFA-100 is an effective screening strategy for von Willebrand disease, though VWF:RCo remains the reference for subtype classification.
We evaluated the use of the turbidimetric HemosIL von Willebrand Factor (VWF) Activity assay (VWF:Act) on the STA-R automated coagulometer (Stago, Asnières, France) for the diagnosis of von Willebrand disease (VWD). For this, we prospectively screened 268 patients. As a second part, we retrospectively assayed 111 patients with well-defined VWD subtype. In the first prospective study, we demonstrate that in most cases of VWD, VWF ristocetin cofactor activity (VWF:RCo) and VWF:Act are highly correlated but that they both cannot be considered a good screening assay when used alone, since they could miss about 25% of VWF abnormalities. However, the association of VWF:Act analysis and the Platelet Function Analyzer-100 (PFA-100) test constitutes an excellent screening strategy. In our second retrospective study concerning VWD subtypes, VWF:RCo and VWF:Act were well correlated but could be very discrepant, especially for some cases of type 2M VWD. We consider that VWF:RCo remains the "reference assay" for VWD subtype classification.
No takes yet. Share an insight, caveat, or question.
Trossaërt et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: